{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:18:06Z","timestamp":1791505086359,"version":"4.3.4"},"reference-count":123,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Mol Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Precision oncology has emerged as a promising strategy for treating high-grade gliomas, yet its clinical impact has been disappointing, with over 300 clinical trials on targeted therapies failing to yield substantial improvements in patient outcomes. Current approaches primarily focus on static, marker-driven tumor features, which capture only a small portion of the complex biology that governs therapeutic responses. Functional precision oncology (FPO) offers a complementary approach, enhancing treatment selection in a personalized manner by dynamically testing patient-derived tumor cells against a range of available therapeutic agents. Here this review examines both historical and contemporary treatment strategies for high-grade gliomas and explores underlying reasons for the limited success of multiple precision oncology initiatives. We demonstrate how the incorporation of FPO in the armamentarium of glioma therapies may address these challenges and outline its proposed role as well as the practical considerations in utilizing FPO for clinical decision-making in patients with glioma.<\/jats:p>","DOI":"10.1038\/s12276-025-01614-x","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T01:04:28Z","timestamp":1767834268000},"page":"43-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The functional imperative in high-grade glioma"],"prefix":"10.1038","volume":"58","author":[{"given":"Laura Shih Hui","family":"Goh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1325-4347","authenticated-orcid":false,"given":"Dexter Kai Hao","family":"Thng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne Li En","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0292-6985","authenticated-orcid":false,"given":"Tan Boon","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Li Ann","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"1614_CR1","doi-asserted-by":"publisher","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","volume":"86","author":"AM Tsimberidou","year":"2020","unstructured":"Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Review of precision cancer medicine: Evolution of the treatment paradigm. Cancer Treat. Rev. 86, 102019 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"1614_CR2","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"The Cancer Genome Atlas Research Network","year":"2008","unstructured":"The Cancer Genome Atlas Research Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061\u20131068 (2008).","journal-title":"Nature"},{"key":"1614_CR3","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","volume":"23","author":"DN Louis","year":"2021","unstructured":"Louis, D. N. et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 23, 1231\u20131251 (2021).","journal-title":"Neuro Oncol."},{"key":"1614_CR4","doi-asserted-by":"publisher","unstructured":"Cruz Da Silva, E., Mercier, M. C., Etienne-Selloum, N., Dontenwill, M. & Choulier, L. A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers https:\/\/doi.org\/10.3390\/cancers13081795 (2021).","DOI":"10.3390\/cancers13081795"},{"key":"1614_CR5","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s10072-024-07350-w","volume":"45","author":"G Sferruzza","year":"2024","unstructured":"Sferruzza, G. et al. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives. Neurol. Sci. 45, 2561\u20132578 (2024).","journal-title":"Neurol. Sci."},{"key":"1614_CR6","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","volume":"20","author":"JC Marine","year":"2020","unstructured":"Marine, J. C., Dawson, S. J. & Dawson, M. A. Non-genetic mechanisms of therapeutic resistance in cancer. Nat. Rev. Cancer 20, 743\u2013756 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"1614_CR7","doi-asserted-by":"publisher","first-page":"703764","DOI":"10.3389\/fonc.2021.703764","volume":"11","author":"A Comba","year":"2021","unstructured":"Comba, A. et al. Uncovering spatiotemporal heterogeneity of high-grade gliomas: from disease biology to therapeutic implications. Front. Oncol. 11, 703764 (2021).","journal-title":"Front. Oncol."},{"key":"1614_CR8","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/noac202","volume":"24","author":"QT Ostrom","year":"2022","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015\u20132019. Neuro Oncol. 24, v1\u2013v95 (2022).","journal-title":"Neuro Oncol."},{"key":"1614_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987\u2013996 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR10","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1200\/JCO.22.01785","volume":"41","author":"JPS Knisely","year":"2023","unstructured":"Knisely, J. P. S. & Fine, H. A. Reirradiation for recurrent glioblastoma: what we know and what we do not. J. Clin. Oncol. 41, 1183\u20131188 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1614_CR11","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3171\/jns.1978.49.3.0333","volume":"49","author":"MD Walker","year":"1978","unstructured":"Walker, M. D. et al. Evaluation of BCNU and\/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J. Neurosurg. 49, 333\u2013343 (1978).","journal-title":"J. Neurosurg."},{"key":"1614_CR12","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","volume":"87","author":"M Weller","year":"2020","unstructured":"Weller, M. & Le Rhun, E. How did lomustine become standard of care in recurrent glioblastoma? Cancer Treat. Rev. 87, 102029 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"1614_CR13","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1002\/1097-0142(197505)35:5<1398::AID-CNCR2820350524>3.0.CO;2-C","volume":"35","author":"PH Gutin","year":"1975","unstructured":"Gutin, P. H. et al. Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors. Cancer 35, 1398\u20131404 (1975).","journal-title":"Cancer"},{"key":"1614_CR14","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1001\/jama.1979.03290360032023","volume":"241","author":"FH Hochberg","year":"1979","unstructured":"Hochberg, F. H., Linggood, R., Wolfson, L., Baker, W. H. & Kornblith, P. Quality and duration of survival in glioblastoma multiforme. Combined surgical, radiation, and lomustine therapy. JAMA 241, 1016\u20131018 (1979).","journal-title":"JAMA"},{"key":"1614_CR15","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1056\/NEJM198012043032303","volume":"303","author":"MD Walker","year":"1980","unstructured":"Walker, M. D. et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med. 303, 1323\u20131329 (1980).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR16","first-page":"121","volume":"67","author":"SB Green","year":"1983","unstructured":"Green, S. B. et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep. 67, 121\u2013132 (1983).","journal-title":"Cancer Treat. Rep."},{"key":"1614_CR17","first-page":"vdad174","volume":"6","author":"G Sferruzza","year":"2024","unstructured":"Sferruzza, G., Malcangi, M., Bosco, L. & Finocchiaro, G. Reassessing the efficacy of bevacizumab in newly diagnosed glioblastoma: a systematic review and external pseudodata-based analysis. Neurooncol. Adv. 6, vdad174 (2024).","journal-title":"Neurooncol. Adv."},{"key":"1614_CR18","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733\u20134740 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1614_CR19","doi-asserted-by":"publisher","unstructured":"Vaz-Salgado, M. A. et al. Recurrent glioblastoma: a review of the treatment options. Cancers https:\/\/doi.org\/10.3390\/cancers15174279 (2023).","DOI":"10.3390\/cancers15174279"},{"key":"1614_CR20","doi-asserted-by":"publisher","unstructured":"Khagi, S. et al. Recent advances in tumor treating fields (TTFields) therapy for glioblastoma. Oncologist https:\/\/doi.org\/10.1093\/oncolo\/oyae227 (2025).","DOI":"10.1093\/oncolo\/oyae227"},{"key":"1614_CR21","doi-asserted-by":"publisher","first-page":"111395","DOI":"10.1016\/j.jocn.2025.111395","volume":"138","author":"DJ Crompton","year":"2025","unstructured":"Crompton, D. J. et al. Tumor treating fields utilization and efficacy for glioblastoma at a large multicenter academic practice. J Clin Neurosci 138, 111395 (2025).","journal-title":"J Clin Neurosci"},{"key":"1614_CR22","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11060-025-04946-w","volume":"173","author":"DC Riegel","year":"2025","unstructured":"Riegel, D. C., Bureau, B. L., Conlon, P., Chavez, G. & Connelly, J. M. Long-term survival, patterns of progression, and patterns of use for patients with newly diagnosed glioblastoma treated with or without Tumor Treating Fields (TTFields) in a real-world setting. J. Neurooncol. 173, 49\u201357 (2025).","journal-title":"J. Neurooncol."},{"key":"1614_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12042-x","volume":"24","author":"P Kumthekar","year":"2024","unstructured":"Kumthekar, P. et al. A qualitative evaluation of factors influencing tumor treating fields (TTFields) therapy decision making among brain tumor patients and physicians. BMC Cancer 24, 527 (2024).","journal-title":"BMC Cancer"},{"key":"1614_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1093\/neuonc\/nox191","volume":"20","author":"E Eskilsson","year":"2018","unstructured":"Eskilsson, E. et al. EGFR heterogeneity and implications for therapeutic intervention in glioblastoma. Neuro Oncol. 20, 743\u2013752 (2018).","journal-title":"Neuro Oncol."},{"key":"1614_CR25","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1124\/jpet.110.167601","volume":"334","author":"S Agarwal","year":"2010","unstructured":"Agarwal, S., Sane, R., Gallardo, J. L., Ohlfest, J. R. & Elmquist, W. F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J. Pharmacol. Exp. Ther. 334, 147\u2013155 (2010).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"1614_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00280-012-1929-4","volume":"70","author":"Y Togashi","year":"2012","unstructured":"Togashi, Y. et al. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother. Pharmacol. 70, 399\u2013405 (2012).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"1614_CR27","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cllc.2012.06.004","volume":"14","author":"J Zhao","year":"2013","unstructured":"Zhao, J. et al. Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma. Clin. Lung Cancer 14, 188\u2013193 (2013).","journal-title":"Clin. Lung Cancer"},{"key":"1614_CR28","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/neuonc\/not247","volume":"16","author":"PY Wen","year":"2014","unstructured":"Wen, P. Y. et al. Phase I\/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 16, 567\u2013578 (2014).","journal-title":"Neuro Oncol."},{"key":"1614_CR29","doi-asserted-by":"publisher","first-page":"3290","DOI":"10.1200\/JCO.2018.78.3118","volume":"36","author":"T Reungwetwattana","year":"2018","unstructured":"Reungwetwattana, T. et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J. Clin. Oncol. 36, 3290\u20133297 (2018).","journal-title":"J. Clin. Oncol"},{"key":"1614_CR30","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"JC Soria","year":"2018","unstructured":"Soria, J. C. et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med 378, 113\u2013125 (2018).","journal-title":"N Engl J Med"},{"key":"1614_CR31","doi-asserted-by":"publisher","unstructured":"Villanacci, F. et al. Resistance of recurrent epidermal growth factor receptor-altered glioblastoma to anti-epidermal growth factor receptor targeted therapy with osimertinib. Oncologist https:\/\/doi.org\/10.1093\/oncolo\/oyaf146 (2025).","DOI":"10.1093\/oncolo\/oyaf146"},{"key":"1614_CR32","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1002\/gcc.23143","volume":"62","author":"A Boongird","year":"2023","unstructured":"Boongird, A. et al. Glioblastoma with novel EGFR mutations (T790M and exon 20 insertion) yet unresponsive to osimertinib: a case report. Genes Chromosomes Cancer 62, 423\u2013429 (2023).","journal-title":"Genes Chromosomes Cancer"},{"key":"1614_CR33","doi-asserted-by":"publisher","first-page":"CNS43","DOI":"10.2217\/cns-2019-0014","volume":"8","author":"I Makhlin","year":"2019","unstructured":"Makhlin, I. et al. Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma. CNS Oncol. 8, CNS43 (2019).","journal-title":"CNS Oncol."},{"key":"1614_CR34","doi-asserted-by":"publisher","first-page":"TPS9156","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9156","volume":"41","author":"ML Johnson","year":"2023","unstructured":"Johnson, M. L. et al. A phase 1 study to assess BDTX-1535, an oral EGFR inhibitor, in patients with glioblastoma or non-small-cell lung cancer. J. Clin. Oncol. 41, TPS9156\u2013TPS9156 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1614_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/neuonc\/noac173","volume":"25","author":"AB Lassman","year":"2023","unstructured":"Lassman, A. B. et al. Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: a phase III randomized clinical trial. Neuro Oncol. 25, 339\u2013350 (2023).","journal-title":"Neuro Oncol."},{"key":"1614_CR36","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/neuonc\/nov013","volume":"17","author":"MJ van den Bent","year":"2015","unstructured":"van den Bent, M. J. et al. Changes in the EGFR amplification and EGFRvIII expression between paired primary and recurrent glioblastomas. Neuro Oncol. 17, 935\u2013941 (2015).","journal-title":"Neuro Oncol."},{"key":"1614_CR37","doi-asserted-by":"publisher","first-page":"4722","DOI":"10.1200\/JCO.2010.28.6963","volume":"28","author":"JH Sampson","year":"2010","unstructured":"Sampson, J. H. et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 28, 4722\u20134729 (2010).","journal-title":"J. Clin. Oncol."},{"key":"1614_CR38","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/neuonc\/nov078","volume":"17","author":"SP Niclou","year":"2015","unstructured":"Niclou, S. P. Gauging heterogeneity in primary versus recurrent glioblastoma. Neuro Oncol. 17, 907\u2013909 (2015).","journal-title":"Neuro Oncol."},{"key":"1614_CR39","doi-asserted-by":"publisher","unstructured":"Oda, K., Matsuoka, Y., Funahashi, A. & Kitano, H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol. Syst. Biol. https:\/\/doi.org\/10.1038\/msb4100014 (2005).","DOI":"10.1038\/msb4100014"},{"key":"1614_CR40","doi-asserted-by":"publisher","first-page":"33440","DOI":"10.18632\/oncotarget.7961","volume":"7","author":"X Li","year":"2016","unstructured":"Li, X. et al. PI3K\/Akt\/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7, 33440\u201333450 (2016).","journal-title":"Oncotarget"},{"key":"1614_CR41","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz, D. N. et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381, 125\u2013132 (2013).","journal-title":"Lancet"},{"key":"1614_CR42","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1093\/neuonc\/noq052","volume":"12","author":"D Akhavan","year":"2010","unstructured":"Akhavan, D., Cloughesy, T. F. & Mischel, P. S. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 12, 882\u2013889 (2010).","journal-title":"Neuro Oncol."},{"key":"1614_CR43","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1158\/0008-5472.CAN-23-0186","volume":"83","author":"ER Jackson","year":"2023","unstructured":"Jackson, E. R. et al. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma. Cancer Res. 83, 2421\u20132437 (2023).","journal-title":"Cancer Res."},{"key":"1614_CR44","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1093\/neuonc\/noad117","volume":"25","author":"EK Noch","year":"2023","unstructured":"Noch, E. K. et al. Insulin feedback is a targetable resistance mechanism of PI3K inhibition in glioblastoma. Neuro Oncol. 25, 2165\u20132176 (2023).","journal-title":"Neuro Oncol."},{"key":"1614_CR45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00401-011-0802-6","volume":"121","author":"G Schindler","year":"2011","unstructured":"Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397\u2013405 (2011).","journal-title":"Acta Neuropathol."},{"key":"1614_CR46","first-page":"vdac174","volume":"4","author":"G Arbour","year":"2022","unstructured":"Arbour, G. et al. Upfront BRAF\/MEK inhibitors for treatment of high-grade glioma: a case report and review of the literature. Neurooncol. Adv. 4, vdac174 (2022).","journal-title":"Neurooncol. Adv."},{"key":"1614_CR47","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S1470-2045(21)00578-7","volume":"23","author":"PY Wen","year":"2022","unstructured":"Wen, P. Y. et al. Dabrafenib plus trametinib in patients with BRAF(V600E)-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. Lancet Oncol. 23, 53\u201364 (2022).","journal-title":"Lancet Oncol."},{"key":"1614_CR48","doi-asserted-by":"publisher","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-11-1243","volume":"71","author":"J Villanueva","year":"2011","unstructured":"Villanueva, J., Vultur, A. & Herlyn, M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 71, 7137\u20137140 (2011).","journal-title":"Cancer Res."},{"key":"1614_CR49","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1056\/NEJMoa2304194","volume":"389","author":"IK Mellinghoff","year":"2023","unstructured":"Mellinghoff, I. K. et al. Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N. Engl. J. Med. 389, 589\u2013601 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR50","doi-asserted-by":"publisher","first-page":"e0242780","DOI":"10.1371\/journal.pone.0242780","volume":"15","author":"H Tegally","year":"2020","unstructured":"Tegally, H. et al. Discovering novel driver mutations from pan-cancer analysis of mutational and gene expression profiles. PLoS ONE 15, e0242780 (2020).","journal-title":"PLoS ONE"},{"key":"1614_CR51","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.cell.2020.01.032","volume":"180","author":"S Kumar","year":"2020","unstructured":"Kumar, S. et al. Passenger mutations in more than 2,500 cancer genomes: overall molecular functional impact and consequences. Cell 180, 915\u2013927 e916 (2020).","journal-title":"Cell"},{"key":"1614_CR52","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/s41586-020-2175-2","volume":"582","author":"Y Saito","year":"2020","unstructured":"Saito, Y. et al. Landscape and function of multiple mutations within individual oncogenes. Nature 582, 95\u201399 (2020).","journal-title":"Nature"},{"key":"1614_CR53","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.molmed.2023.03.007","volume":"29","author":"D Ostroverkhova","year":"2023","unstructured":"Ostroverkhova, D., Przytycka, T. M. & Panchenko, A. R. Cancer driver mutations: predictions and reality. Trends Mol. Med. 29, 554\u2013566 (2023).","journal-title":"Trends Mol. Med."},{"key":"1614_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34746-z","volume":"13","author":"M Bostrom","year":"2022","unstructured":"Bostrom, M. & Larsson, E. Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer. Nat. Commun. 13, 7023 (2022).","journal-title":"Nat. Commun."},{"key":"1614_CR55","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","volume":"17","author":"RG Verhaak","year":"2010","unstructured":"Verhaak, R. G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98\u2013110 (2010).","journal-title":"Cancer Cell"},{"key":"1614_CR56","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cell.2019.06.024","volume":"178","author":"C Neftel","year":"2019","unstructured":"Neftel, C. et al. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178, 835\u2013849 e821 (2019).","journal-title":"Cell"},{"key":"1614_CR57","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.trecan.2020.01.009","volume":"6","author":"BC Prager","year":"2020","unstructured":"Prager, B. C., Bhargava, S., Mahadev, V., Hubert, C. G. & Rich, J. N. Glioblastoma stem cells: driving resilience through chaos. Trends Cancer 6, 223\u2013235 (2020).","journal-title":"Trends Cancer"},{"key":"1614_CR58","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao, S. et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444, 756\u2013760 (2006).","journal-title":"Nature"},{"key":"1614_CR59","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-23-4024","volume":"84","author":"G MacLeod","year":"2024","unstructured":"MacLeod, G. et al. Fitness screens map state-specific glioblastoma stem cell vulnerabilities. Cancer Res. 84, 3967\u20133983 (2024).","journal-title":"Cancer Res."},{"key":"1614_CR60","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/s41392-023-01589-z","volume":"8","author":"X Xie","year":"2023","unstructured":"Xie, X. et al. Recent advances in targeting the \u201cundruggable\u201d proteins: from drug discovery to clinical trials. Signal Transduct. Target. Ther. 8, 335 (2023).","journal-title":"Signal Transduct. Target. Ther."},{"key":"1614_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.neuropharm.2016.03.021","volume":"120","author":"VK Gribkoff","year":"2017","unstructured":"Gribkoff, V. K. & Kaczmarek, L. K. The need for new approaches in CNS drug discovery: why drugs have failed, and what can be done to improve outcomes. Neuropharmacology 120, 11\u201319 (2017).","journal-title":"Neuropharmacology"},{"key":"1614_CR62","first-page":"vdae201","volume":"7","author":"AM Giantini-Larsen","year":"2025","unstructured":"Giantini-Larsen, A. M. et al. Therapeutic manipulation and bypass of the blood-brain barrier: powerful tools in glioma treatment. Neurooncol. Adv. 7, vdae201 (2025).","journal-title":"Neurooncol. Adv."},{"key":"1614_CR63","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.ejca.2018.06.035","volume":"101","author":"A Hazim","year":"2018","unstructured":"Hazim, A. & Prasad, V. A pooled analysis of published, basket trials in cancer medicine. Eur. J. Cancer 101, 244\u2013250 (2018).","journal-title":"Eur. J. Cancer"},{"key":"1614_CR64","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1056\/NEJMra1510062","volume":"377","author":"J Woodcock","year":"2017","unstructured":"Woodcock, J. & LaVange, L. M. Master protocols to study multiple therapies, multiple diseases, or both. N. Engl. J. Med. 377, 62\u201370 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1614_CR65","doi-asserted-by":"crossref","unstructured":"Corrigendum to: The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: lessons for genomic trial design. J. Natl Cancer Inst. 114, 325, (2022).","DOI":"10.1093\/jnci\/djab115"},{"key":"1614_CR66","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/jnci\/djaf015","volume":"117","author":"I Zerdes","year":"2025","unstructured":"Zerdes, I. et al. Comprehensive genome profiling for treatment decisions in patients with metastatic tumors: real-world evidence meta-analysis and registry data implementation. J. Natl Cancer Inst. 117, 1117\u20131124 (2025).","journal-title":"J. Natl Cancer Inst."},{"key":"1614_CR67","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1016\/j.trecan.2024.08.005","volume":"10","author":"BN Gantner","year":"2024","unstructured":"Gantner, B. N. et al. Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes. Trends Cancer 10, 992\u20131008 (2024).","journal-title":"Trends Cancer"},{"key":"1614_CR68","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1177\/1535370218794365","volume":"243","author":"MX Duval","year":"2018","unstructured":"Duval, M. X. The inadequacy of the reductionist approach in discovering new therapeutic agents against complex diseases. Exp. Biol. Med. 243, 1004\u20131013 (2018).","journal-title":"Exp. Biol. Med."},{"key":"1614_CR69","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.ccell.2022.08.011","volume":"40","author":"D Akhoundova","year":"2022","unstructured":"Akhoundova, D. & Rubin, M. A. Clinical application of advanced multi-omics tumor profiling: ahaping precision oncology of the future. Cancer Cell 40, 920\u2013938 (2022).","journal-title":"Cancer Cell"},{"key":"1614_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-09742-0","volume":"15","author":"Y Ding","year":"2025","unstructured":"Ding, Y. et al. Comprehensive multi-omics and machine learning framework for glioma subtyping and precision therapeutics. Sci. Rep. 15, 24874 (2025).","journal-title":"Sci. Rep."},{"key":"1614_CR71","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s43018-022-00510-x","volume":"4","author":"S Migliozzi","year":"2023","unstructured":"Migliozzi, S. et al. Integrative multi-omics networks identify PKCdelta and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. Nat. Cancer 4, 181\u2013202 (2023).","journal-title":"Nat. Cancer"},{"key":"1614_CR72","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ccell.2023.12.015","volume":"42","author":"KH Kim","year":"2024","unstructured":"Kim, K. H. et al. Integrated proteogenomic characterization of glioblastoma evolution. Cancer Cell 42, 358\u2013377 e358 (2024).","journal-title":"Cancer Cell"},{"key":"1614_CR73","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ccell.2021.01.006","volume":"39","author":"LB Wang","year":"2021","unstructured":"Wang, L. B. et al. Proteogenomic and metabolomic characterization of human glioblastoma. Cancer Cell 39, 509\u2013528 e520 (2021).","journal-title":"Cancer Cell"},{"key":"1614_CR74","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1038\/nm.4389","volume":"23","author":"A Letai","year":"2017","unstructured":"Letai, A. Functional precision cancer medicine-moving beyond pure genomics. Nat. Med. 23, 1028\u20131035 (2017).","journal-title":"Nat. Med."},{"key":"1614_CR75","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai, A., Bhola, P. & Welm, A. L. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell 40, 26\u201335 (2022).","journal-title":"Cancer Cell"},{"key":"1614_CR76","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1158\/1541-7786.MCR-21-0255","volume":"20","author":"C Pauli","year":"2022","unstructured":"Pauli, C. et al. A functional precision oncology approach to identify treatment strategies for myxofibrosarcoma patients. Mol. Cancer Res. 20, 244\u2013252 (2022).","journal-title":"Mol. Cancer Res."},{"key":"1614_CR77","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41588-020-00750-6","volume":"53","author":"XY Woo","year":"2021","unstructured":"Woo, X. Y. et al. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nat. Genet. 53, 86\u201399 (2021).","journal-title":"Nat. Genet."},{"key":"1614_CR78","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.celrep.2012.12.013","volume":"3","author":"KM Joo","year":"2013","unstructured":"Joo, K. M. et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep. 3, 260\u2013273 (2013).","journal-title":"Cell Rep."},{"key":"1614_CR79","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","volume":"180","author":"F Jacob","year":"2020","unstructured":"Jacob, F. et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell 180, 188\u2013204 e122 (2020).","journal-title":"Cell"},{"key":"1614_CR80","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/nature03128","volume":"432","author":"SK Singh","year":"2004","unstructured":"Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396\u2013401 (2004).","journal-title":"Nature"},{"key":"1614_CR81","doi-asserted-by":"publisher","first-page":"7011","DOI":"10.1158\/0008-5472.CAN-04-1364","volume":"64","author":"R Galli","year":"2004","unstructured":"Galli, R. et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64, 7011\u20137021 (2004).","journal-title":"Cancer Res."},{"key":"1614_CR82","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","volume":"9","author":"J Lee","year":"2006","unstructured":"Lee, J. et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9, 391\u2013403 (2006).","journal-title":"Cancer Cell"},{"key":"1614_CR83","doi-asserted-by":"publisher","unstructured":"Logun, M., Zhao, W., Mao, L. & Karumbaiah, L. Microfluidics in malignant glioma research and precision medicine. Adv. Biosyst. https:\/\/doi.org\/10.1002\/adbi.201700221 (2018).","DOI":"10.1002\/adbi.201700221"},{"key":"1614_CR84","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1038\/s41596-020-0402-9","volume":"15","author":"F Jacob","year":"2020","unstructured":"Jacob, F., Ming, G. L. & Song, H. Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing. Nat. Protoc. 15, 4000\u20134033 (2020).","journal-title":"Nat. Protoc."},{"key":"1614_CR85","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","volume":"30","author":"AM Acanda De La Rocha","year":"2024","unstructured":"Acanda De La Rocha, A. M. et al. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat. Med. 30, 990\u20131000 (2024).","journal-title":"Nat. Med."},{"key":"1614_CR86","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth, C. et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 12, 372\u2013387 (2022).","journal-title":"Cancer Discov."},{"key":"1614_CR87","doi-asserted-by":"publisher","first-page":"5006","DOI":"10.1182\/blood-2023-189856","volume":"142","author":"L Kazianka","year":"2023","unstructured":"Kazianka, L. et al. Functional precision medicine vs genomics vs clinical experience: feasibility results from the multicentric, prospective, randomized controlled Exalt-2 Trial. Blood 142, 5006\u20135006 (2023).","journal-title":"Blood"},{"key":"1614_CR88","doi-asserted-by":"publisher","unstructured":"Acanda de la Rocha, A. M., Berlow, N. E. & Azzam, D. J. Functional precision medicine: the future of cancer care. Trends Mol. Med. https:\/\/doi.org\/10.1016\/j.molmed.2024.10.015 (2024).","DOI":"10.1016\/j.molmed.2024.10.015"},{"key":"1614_CR89","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41571-023-00745-2","volume":"20","author":"AWJ van Renterghem","year":"2023","unstructured":"van Renterghem, A. W. J., van de Haar, J. & Voest, E. E. Functional precision oncology using patient-derived assays: bridging genotype and phenotype. Nat. Rev. Clin. Oncol. 20, 305\u2013317 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1614_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-68801-0","volume":"14","author":"A Ledford","year":"2024","unstructured":"Ledford, A. et al. Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma. Sci. Rep. 14, 19474 (2024).","journal-title":"Sci. Rep."},{"key":"1614_CR91","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1093\/neuonc\/nov198","volume":"17","author":"ME Hegi","year":"2015","unstructured":"Hegi, M. E. & Stupp, R. Withholding temozolomide in glioblastoma patients with unmethylated MGMT promoter-still a dilemma? Neuro Oncol. 17, 1425\u20131427 (2015).","journal-title":"Neuro Oncol."},{"key":"1614_CR92","doi-asserted-by":"publisher","first-page":"e0307818","DOI":"10.1371\/journal.pone.0307818","volume":"19","author":"TB Toh","year":"2024","unstructured":"Toh, T. B. et al. Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol. PLoS ONE 19, e0307818 (2024).","journal-title":"PLoS ONE"},{"key":"1614_CR93","doi-asserted-by":"publisher","first-page":"TPS2097","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2097","volume":"43","author":"AS Berghoff","year":"2025","unstructured":"Berghoff, A. S. et al. Personalized targeted glioblastoma therapies by ex vivo drug screening: Advanced brain tumor therapy clinical trial (ATTRACT). J. Clin. Oncol. 43, TPS2097\u2013TPS2097 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1614_CR94","first-page":"vdaf056","volume":"7","author":"AS Berghoff","year":"2025","unstructured":"Berghoff, A. S. et al. Personalized targeted glioblastoma therapies by ex vivo drug screening: study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT). Neurooncol. Adv. 7, vdaf056 (2025).","journal-title":"Neurooncol. Adv."},{"key":"1614_CR95","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","volume":"25","author":"M Monje","year":"2023","unstructured":"Monje, M. et al. Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium (PBTC-047). Neuro Oncol. 25, 2262\u20132272 (2023).","journal-title":"Neuro Oncol."},{"key":"1614_CR96","doi-asserted-by":"publisher","first-page":"3196","DOI":"10.1038\/s41591-024-03224-y","volume":"30","author":"S Lee","year":"2024","unstructured":"Lee, S. et al. High-throughput identification of repurposable neuroactive drugs with potent anti-glioblastoma activity. Nat. Med. 30, 3196\u20133208 (2024).","journal-title":"Nat. Med."},{"key":"1614_CR97","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","volume":"483","author":"A Prahallad","year":"2012","unstructured":"Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100\u2013103 (2012).","journal-title":"Nature"},{"key":"1614_CR98","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1093\/neuonc\/noae184","volume":"27","author":"A Souberan","year":"2025","unstructured":"Souberan, A. et al. Brain tumoroids: treatment prediction and drug development for brain tumors with fast, reproducible, and easy-to-use personalized models. Neuro Oncol. 27, 415\u2013429 (2025).","journal-title":"Neuro Oncol."},{"key":"1614_CR99","doi-asserted-by":"publisher","first-page":"620962","DOI":"10.3389\/fbioe.2020.620962","volume":"8","author":"CM Moysidou","year":"2020","unstructured":"Moysidou, C. M., Barberio, C. & Owens, R. M. Advances in engineering human tissue models. Front. Bioeng. Biotechnol. 8, 620962 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"1614_CR100","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med. 30, 1320\u20131329 (2024).","journal-title":"Nat. Med."},{"key":"1614_CR101","doi-asserted-by":"publisher","unstructured":"Logun, M. et al. Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy. Cell Stem Cell https:\/\/doi.org\/10.1016\/j.stem.2024.11.010 (2024).","DOI":"10.1016\/j.stem.2024.11.010"},{"key":"1614_CR102","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-15-0843","volume":"15","author":"J O\u2019Neil","year":"2016","unstructured":"O\u2019Neil, J. et al. An unbiased oncology compound screen to identify novel combination strategies. Mol. Cancer Ther. 15, 1155\u20131162 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"1614_CR103","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks, P. et al. Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603, 166\u2013173 (2022).","journal-title":"Nature"},{"key":"1614_CR104","doi-asserted-by":"publisher","first-page":"104752","DOI":"10.1016\/j.ebiom.2023.104752","volume":"95","author":"J Ariey-Bonnet","year":"2023","unstructured":"Ariey-Bonnet, J. et al. Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms. EBioMedicine 95, 104752 (2023).","journal-title":"EBioMedicine"},{"key":"1614_CR105","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1093\/bioinformatics\/btx806","volume":"34","author":"K Preuer","year":"2018","unstructured":"Preuer, K. et al. DeepSynergy: predicting anti-cancer drug synergy with deep learning. Bioinformatics 34, 1538\u20131546 (2018).","journal-title":"Bioinformatics"},{"key":"1614_CR106","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.tranon.2021.101290","volume":"15","author":"L Kohtamaki","year":"2022","unstructured":"Kohtamaki, L. et al. High-throughput ex vivo drug testing identifies potential drugs and drug combinations for NRAS-positive malignant melanoma. Transl. Oncol. 15, 101290 (2022).","journal-title":"Transl. Oncol."},{"key":"1614_CR107","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1158\/2159-8290.CD-22-1377","volume":"13","author":"MA Gouda","year":"2023","unstructured":"Gouda, M. A., Buschhorn, L., Schneeweiss, A., Wahida, A. & Subbiah, V. N-of-1 trials in cancer drug development. Cancer Discov. 13, 1301\u20131309 (2023).","journal-title":"Cancer Discov."},{"key":"1614_CR108","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1634\/theoncologist.2018-0263","volume":"23","author":"M Labots","year":"2018","unstructured":"Labots, M. et al. Selection of protein kinase inhibitors based on tumor tissue kinase activity profiles in patients with refractory solid malignancies: an interventional molecular profiling study. Oncologist 23, 1135\u2013e1118 (2018).","journal-title":"Oncologist"},{"key":"1614_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05531-y","volume":"22","author":"M Mathonnet","year":"2021","unstructured":"Mathonnet, M. et al. ONCOGRAM: study protocol for the evaluation of therapeutic response and survival of metastatic colorectal cancer patients treated according to the guidelines of a chemosensitivity assay, the Oncogramme(R). Trials 22, 556 (2021).","journal-title":"Trials"},{"key":"1614_CR110","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s41591-024-03044-0","volume":"30","author":"LMS Lau","year":"2024","unstructured":"Lau, L. M. S. et al. Precision-guided treatment in high-risk pediatric cancers. Nat. Med. 30, 1913\u20131922 (2024).","journal-title":"Nat. Med."},{"key":"1614_CR111","doi-asserted-by":"publisher","unstructured":"Coffey, D. G. et al. High-throughput drug screening and multi-omic analysis to guide individualized treatment for multiple myeloma. JCO Precis. Oncol. https:\/\/doi.org\/10.1200\/PO.20.00442 (2021).","DOI":"10.1200\/PO.20.00442"},{"key":"1614_CR112","doi-asserted-by":"publisher","first-page":"e70129","DOI":"10.1002\/hem3.70129","volume":"9","author":"L Kazianka","year":"2025","unstructured":"Kazianka, L. et al. Comparing functional and genomic-based precision medicine in blood cancer patients. Hemasphere 9, e70129 (2025).","journal-title":"Hemasphere"},{"key":"1614_CR113","doi-asserted-by":"publisher","first-page":"TPS359","DOI":"10.1200\/JCO.2021.39.3_suppl.TPS359","volume":"39","author":"A Diehl","year":"2021","unstructured":"Diehl, A., Harris, W. P. & King, G. T. Trial in progress: A feasibility study of multi-platform profiling using biospecimens from patients with resected biliary tract cancer. J. Clin. Oncol. 39, TPS359\u2013TPS359 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1614_CR114","doi-asserted-by":"publisher","first-page":"S225","DOI":"10.1016\/j.annonc.2023.09.1407","volume":"34","author":"G King","year":"2023","unstructured":"King, G. et al. 114P Prospective longitudinal tumor-informed ctDNA in resectable biliary tract cancers. Ann. Oncol.34, S225 (2023).","journal-title":"Ann. Oncol."},{"key":"1614_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00851-7","volume":"9","author":"SPY Chan","year":"2025","unstructured":"Chan, S. P. Y. et al. Functional combinatorial precision medicine for predicting and optimizing soft tissue sarcoma treatments. npj Precis. Oncol. 9, 83 (2025).","journal-title":"npj Precis. Oncol."},{"key":"1614_CR116","doi-asserted-by":"publisher","first-page":"e2304460","DOI":"10.1002\/advs.202304460","volume":"11","author":"H Sun","year":"2024","unstructured":"Sun, H. et al. Prediction of clinical precision chemotherapy by patient-derived 3D bioprinting models of colorectal cancer and its liver metastases. Adv. Sci. 11, e2304460 (2024).","journal-title":"Adv. Sci."},{"key":"1614_CR117","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s13046-024-03052-5","volume":"43","author":"L Varinelli","year":"2024","unstructured":"Varinelli, L. et al. Colorectal carcinoma peritoneal metastases-derived organoids: results and perspective of a model for tailoring hyperthermic intraperitoneal chemotherapy from bench-to-bedside. J. Exp. Clin. Cancer Res. 43, 132 (2024).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"1614_CR118","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/j.annonc.2025.05.024","volume":"36","author":"F Jaulin","year":"2025","unstructured":"Jaulin, F. et al. 12P ORGANOTREAT-01: a pioneer phase I\/II multicenter trial of organoid-driven precision medicine for refractory colorectal cancer. Ann. Oncol. 36, S9\u2013S10 (2025).","journal-title":"Ann. Oncol."},{"key":"1614_CR119","doi-asserted-by":"crossref","first-page":"A105","DOI":"10.1136\/ijgc-2020-002150","volume":"31","author":"H Wang","year":"2021","unstructured":"Wang, H., He, M., Zhong, L. & Zou, D. EPV191\/# 327 Drug screening of patient-derived organoids from ovarian cancer culture to personalized therapy, an exploratory research. Int. J. Gynecol. Cancer 31, A105\u2013A106 (2021).","journal-title":"Int. J. Gynecol. Cancer"},{"key":"1614_CR120","doi-asserted-by":"publisher","first-page":"e2300724","DOI":"10.1200\/PO.23.00724","volume":"8","author":"C Vaklavas","year":"2024","unstructured":"Vaklavas, C. et al. TOWARDS study: patient-derived xenograft engraftment predicts poor survival in patients with newly diagnosed triple-negative breast cancer. JCO Precis. Oncol. 8, e2300724 (2024).","journal-title":"JCO Precis. Oncol"},{"key":"1614_CR121","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-023-01262-1","volume":"23","author":"R Seiler","year":"2023","unstructured":"Seiler, R. et al. Guidance of adjuvant instillation in intermediate-risk non-muscle invasive bladder cancer by drug screens in patient derived organoids: a single center, open-label, phase II trial. BMC Urol. 23, 89 (2023).","journal-title":"BMC Urol."},{"key":"1614_CR122","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1200\/JCO.2024.42.16_suppl.1551","volume":"42","author":"N Berlow","year":"2024","unstructured":"Berlow, N. et al. Clinical utility and accessibility of functional precision medicine for relapsed\/refractory pediatric and adult cancers. J. Clin. Oncol. 42, 1551\u20131551 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1614_CR123","doi-asserted-by":"publisher","first-page":"S1177","DOI":"10.1016\/j.annonc.2023.09.1329","volume":"34","author":"MM Rahman","year":"2023","unstructured":"Rahman, M. M. et al. 2302P Efficacy assessment of targeted and immunotherapies for personalised treatment of melanoma using 2D and 3D ex-vivo assays. Ann. Oncol. 34, S1177 (2023).","journal-title":"Ann. Oncol."}],"container-title":["Experimental &amp; Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01614-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01614-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01614-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:15:57Z","timestamp":1774419357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s12276-025-01614-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":123,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1038\/s12276-025-01614-x","relation":{},"ISSN":["2092-6413"],"issn-type":[{"value":"2092-6413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"assertion":[{"value":"9 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.H. is a scientific co-founder and shareholder of KYAN Technologies, which has licensed intellectual property pertaining to AI-based oncology drug development and functional precision medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}